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ABSTRACT 
Bovine hemoglobin was selected for use in the generation of bioactive hydrolysates with 
potential for use as functional food ingredients for prevention of disorders such as 
hypertension, obesity and diabetes. Bovine hemoglobin was isolated and hydrolysed with 
papain, which was selected using in silico analysis. The generated hydrolysate was enriched 
by ultrafiltration and further purified by high performance liquid chromatography. A number 
of peptides were identified using de novo peptide sequencing and these peptides were 
chemically synthesised to confirm their bioactivity in vitro. Three multifunctional peptides 
with both, angiotensin-I-converting enzyme- (ACE-I) and renin-inhibitory properties and one 
peptide with ACE-I-inhibiting properties were identified. These included the di-peptide HR 
with ACE-I and renin IC50 values of 0.19 and 7.09 mM, respectively. The generated papain 
hydrolysate of bovine hemoglobin not only inhibited the enzymes ACE-I and renin but also 
the enzyme dipeptidyl peptidase-IV (DPP-IV), which has been linked to type-2 diabetes. 
PRACTICAL APPLICATIONS 
Slaughterhouse blood represents a problematic co-product to meat processors due to the large 
volumes generated and its high pollutant load, and it is usually discarded as waste or used for 
low value purposes such as blood meal. However, bovine blood represents a valuable source 
of protein which is underutilized in the food industry. In order to find potential applications 
for this largely underutilized co-product, the ACE-I, renin, and DPP-IV inhibitory properties 
of a papain hydrolysate of bovine hemoglobin were studied and a number of novel 
multifunctional bioactive hydrolysates and peptides were identified. Results obtained may not 
only reduce blood disposal but also have a role in improving public health. In addition, this 
study demonstrates the potential of bovine hemoglobin as a resource for generation of 
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bioactive peptides and opens new commercial opportunities for its use beyond current 
applications in the food industry. 
 
Keywords: hemoglobin, bioactive peptides, renin, ACE-I, hypertension, DPP-IV.  
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INTRODUCTION 
The inhibition of enzymes involved in the renin-angiotensin-aldosterone system (RAAS) 
such as angiotensin-I-converting enzyme (ACE-I; EC 3.4.15.1) and renin (EC 3.4.23.15) 
plays a key role in the treatment of hypertension. In addition, a new approach in the 
management of type-2 diabetes is inhibition of the enzyme dipeptidyl peptidase-IV (DPP-IV; 
EC 3.4.14.5). DPP-IV degrades and inactivates glucagon-like peptide-1 (GLP-1) and gastric-
inhibitory peptide (GIP), two incretin hormones which contribute to the enhancement of 
glucose-induced insulin secretion (Drucker 2006). Various chemically synthesised DPP-IV 
inhibitors are at different stages of development and registration worldwide (Mkele 2013), 
and common antihypertensive drugs such as Captopril®, Enalapril®, Tekturna®, and 
Rasilez® are used as pharmaceutical agents in the control of ACE-I and renin. However, 
DPP-IV, ACE-I, and renin can be inhibited using naturally sourced compounds including 
bioactive peptides derived from food sources, with milder side-effects compared to their 
chemically synthesised counterparts (Danquah and Agyei 2012).  
Bioactive peptides are short sequences of amino acids that are inactive within the sequence of 
the parent protein but have positive impacts on systems of the body including the circulatory, 
gastrointestinal, and nervous system once released (Korhonen and Pihlanto 2006). Such 
peptides can be released by chemical or enzymatic hydrolysis and have been generated from 
a wide variety of natural compounds such as milk (Hernández-Ledesma et al. 2014), fish 
(Mora and Hayes 2015), and co-products of the meat industry including meat, bone, and 
blood (Bah et al. 2013, Lafarga and Hayes 2014). The use of bioactive peptides as ingredients 
in the functional foods industry, as well as nutraceuticals or pharmaceutical agents has gained 
much interest in recent years, and may provide a commercial opportunity for many 
companies (Lalor and Wall 2011). 
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Blood proteins are not only used in the food industry as ingredients in numerous foods, but 
also as binders, natural colour enhancers, emulsifiers, and fat replacers (Bah et al. 2013). 
Blood proteins are also used in the pharmaceutical industry (Xie et al. 2012). For example, 
hemoglobin is the main constituent of Proferrin® (Colorado Biolabs, Inc., CO, USA), a heme 
iron supplement used to address iron deficiency (Hudson and Schonder 2002). However, 
blood is largely underutilized as a protein source and only 30% of the blood generated in 
slaughterhouses is used in the food industry (Bah et al. 2013). As well as being an excellent 
source of iron, hemoglobin is a major constituent protein found in blood and therefore a 
potential resource for the generation of bioactive hydrolysates and peptides for use as 
functional ingredients (Bah et al. 2013, Lafarga and Hayes 2014). Indeed, previous studies 
have demonstrated the potential of blood-derived peptides and have reported physiological 
bioactivities including antioxidant, antihypertensive, and antimicrobial properties (Bah et al. 
2013, Lafarga and Hayes 2014).  
The aim of this work was to generate and characterize a papain (EC 3.4.22.2) hydrolysate of 
bovine hemoglobin and to assess its DPP-IV, ACE-I, and renin inhibitory activities in vitro. 
The generated hydrolysate was enriched by molecular weight cut-off (MWCO) filtration and 
further purified by high performance liquid chromatography (HPLC). A number of peptides 
were identified by de novo peptide sequencing and were chemically synthesised for 
confirmation of bioactivity in vitro. Moreover, the concentration of peptide required to inhibit 
the activity of ACE-I and renin by half (IC50) was calculated for active peptides and their 
bitterness and resistance to gastrointestinal digestion were predicted using Ney’s ‘Q rule’ 
(Ney 1971) and ExPASy PeptideCutter (Gasteiger et al. 2003), respectively.  
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MATERIALS AND METHODS 
Materials and reagents 
Formic acid (FA), dimethyl sulfoxide (DMSO), acetonitrile (ACN), sodium citrate, 
chloroform, papain from Carica papaya, the specific renin inhibitor Z-Arg-Arg-Pro-Phe-His-
Sta-Ile-His-Lys-(Boc)-OMe, and the ACE-I inhibitor Captopril® were supplied by Sigma 
Aldrich (Dublin, Ireland). The DPP-IV inhibitor screening assay kit, containing the DPP-IV 
inhibitor Sitagliptin, and the renin inhibitor screening assay kit were supplied by Cambridge 
BioSciences (Cambridge, England, UK). The ACE-I inhibition assay kit was supplied by 
NBS Biologicals Ltd. (Cambridgeshire, England, UK). All other chemicals used were of 
analytical grade. 
Protein isolation  
Whole bovine blood was collected at time of slaughter under hygienic conditions at the 
abattoir at the Teagasc Food Research Centre, Ashtown, Dublin 15, Ireland. All animals 
slaughtered were female, Charolais cross heifer breed, and were aged between 23 and 24 
months at the time of slaughter. Sodium citrate solution was used as an anticoagulant and was 
added immediately to blood following collection at a final concentration of 1.5% (w/v). 
Blood was chilled to 4 ºC and handled carefully to minimize hemolysis.  
Whole blood cells were separated from plasma by centrifugation at 4ºC and 10,000 × g for 10 
minutes using a Sigma 6K10 centrifuge (Sigma Laborzentrifugen GmbH, Osterode am Harz, 
Germany). The cellular fraction was frozen and freeze-dried. Hemoglobin was obtained from 
this dehydrated cellular fraction by dilution in distilled water (1:3, w/v) to induce hemolysis, 
following the procedure described in Figure 1. Hemoglobin was extracted using chloroform 
in a chloroform to cellular solution ratio of 1:4 (v/v). The sample was agitated for 10 minutes 
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and subsequently centrifuged at 4 ºC and 5,000 × g for 10 minutes using a Sigma 6K10 
centrifuge (Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany) (Álvarez et al. 
2009). The supernatant containing the hemoglobin was frozen, freeze-dried, and stored at -20 
ºC until further use. 
The total protein content was determined in duplicate using a LECO FP628 Protein analyser 
(LECO Corp., MI, USA) based on the Dumas method and according to AOAC method 
992.15, 1990. The conversion factor of 6.25 was used to convert total nitrogen to protein. The 
total protein content and yields were calculated per litre of blood and are shown in Figure 1. 
Moisture and ash content were determined gravimetrically in accordance with previously 
described methods (Kolar 1992). 
In silico analysis  
The amino acid sequence of the α-chain (UniProt ID: HBA_BOVIN | UniProt AC: P01966) 
and the β-chain of bovine hemoglobin (UniProt ID: HBB_BOVIN | UniProt AC: P02070) 
were accessed from the UniProt database, available at http://www.uniprot.org/. An in silico 
analysis was carried out on these sequences following a previously described method 
(Lafarga et al. 2014). Computer simulations of proteolysis were used to study the 
bioavailability of the studied peptides after simulated gastrointestinal digestion with ExPASy 
PeptideCutter, available at http://web.expasy.org/peptide_cutter/ using enzymes found in the 
gastrointestinal tract including pepsin (pH 1.3 and pH>2; EC 3.4.23.1), trypsin (EC 3.4.21.4), 
and chymotrypsin (EC 3.4.21.1) (Gasteiger et al. 2003). Moreover, the ‘Q rule’ formulated 
by Ney (1971) was used to predict the bitterness of the studied peptides based on its amino 
acid composition, whereby a Q-value was calculated from the solubility data of the individual 
amino acids. 
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Enzymatic hydrolysis 
Papain hydrolysates of bovine hemoglobin were prepared in triplicate using a BioFlo 110 
Modular Benchtop fermenter (New Brunswick Scientific Co., Cambridge, England, UK) with 
agitation, temperature, and pH control. A substrate solution was prepared by resuspending the 
dried hemoglobin in MilliQ purified water at a concentration of 30 g/L at a total volume of 
500 mL. Agitation, temperature, and pH conditions were adjusted to 350 rpm, 65 ºC, and 6.5, 
respectively. The pH was kept constant using 0.1 M NaOH. Once the optimum pH and 
temperature conditions were achieved, the enzyme papain (activity ≥3 U/mg) was added in a 
substrate to enzyme ratio of 100:1 (w/w). After 24 h, papain was heat-deactivated at 95 ºC for 
10 min in a Grant JB Aqua 12 water bath (Grant instruments, England, UK).  
Four protein fractions were generated from the whole papain hydrolysate of bovine 
hemoglobin. Fraction one was termed non-ultrafiltered hydrolysate (HB-NUFH). Fractions 
two, three, and four were obtained by MWCO filtration of the whole hydrolysate using 1, 3, 
and 10 kDa MWCO membranes separately (Millipore, Tullagreen, Carrigtwohill, Co. Cork, 
Ireland). These fractions were labelled as HB-1UFH, HB-3UFH, and HB-10UFH, 
respectively. All fractions were frozen, freeze-dried, and stored at -20 ºC until further use. 
Renin inhibition assay 
This assay was carried out using a renin inhibitor screening assay kit (Cayman Chemical 
Company, MI, USA) in accordance with the manufacturers’ instructions. All fractions were 
assayed at a concentration of 1 mg/mL DMSO in triplicate and standard deviations (S.D.) 
calculated. The known renin inhibitor Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-OMe 
was used as a positive control at a concentration of 1 mg/mL. Fluorescence intensity was 
recorded with a FLUOstar Omega microplate reader (BMG LABTECH GmbH, Offenburg, 
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Germany) using an excitation wavelength of 340 nm and an emission wavelength of 500 nm. 
Renin IC50 values were determined for active peptides and hydrolysates by plotting the 
percentage of renin inhibition as a function of the concentration of test compound. 
ACE-I inhibition assay 
This assay was carried out using an ACE-I inhibitor assay kit (Dojindo Molecular 
Technologies, Inc., Munich, Germany) in accordance with the manufacturers’ instructions. 
All fractions were assayed at a concentration of 1 mg/mL HPLC grade water in triplicate and 
means and S.D. were calculated. Absorbance was measured with a FLUOstar Omega 
microplate reader (BMG LABTECH GmbH, Offenburg, Germany) at 450 nm. ACE-I IC50 
values were determined for active hydrolysates and peptides by plotting the percentage of 
inhibition as a function of the concentration of test compound. 
DPP-IV inhibition assay 
This assay was carried out using a DPP-IV inhibitor screening assay kit in accordance with 
the manufacturers’ instructions (Cayman Chemical Company, MI, USA). All hydrolysates 
were assayed in triplicate and means and S.D. were calculated. The known DPP-IV inhibitor 
sitagliptin was used as a positive control at a final concentration of 0.4 mg/mL, as 
recommended by the manufacturer. Fluorescence intensity was recorded with a FLUOstar 
Omega microplate reader (BMG LABTECH GmbH, Offenburg, Germany) using an 
excitation wavelength of 355 nm and an emission wavelength of 460 nm. 
Protein and peptide identification using mass spectrometry 
A direct infusion of the isolated hemoglobin, dissolved in HPLC grade water at a final 
concentration of 50 g/mL, was carried out in 1:1 ACN:HPLC grade water, containing 0.1% 
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FA, into the electrospray source of the Q-TOF Premier mass spectrometer (Waters Corp., 
Milford, MA, USA). The mass spectra data were acquired in positive ion mode from m/z 600 
to 1400. 
The HB-1UFH hydrolysed fraction was re-suspended in HPLC grade water at a concentration 
of 1 mg/mL and filtered through a 0.45 µm CHROMAFIL® Xtra PVDF-45/25 syringe filter 
(MACHEREY-NAGEL GmbH & Co., Düren, Germany). The filtered hydrolysate was 
analysed on a Q-TOF Premier mass spectrometer (Waters Corp., Milford, MA, USA), 
coupled to an Alliance 2695 HPLC system (Waters Corp., Milford, MA, USA). The 
chromatographic separation was carried out at a flow rate of 0.2 mL/min with an injection 
volume of 10 µL on an Atlantis dC18 column – 100mm × 2.1 mm, 3µm particle size (Waters 
Corp., Milford, MA, USA). Peptides were separated using 0.1% FA in HPLC grade water 
(solvent A) and 0.1% FA in ACN (solvent B). Column temperature was maintained at 40 ºC. 
The gradient program was as follows: (i) 0 min, 98% A; (ii) 0-0.1 min, 98% A; (iii) 0.1-18 
min, 90% A; (iv) 18-20 min, 85% A; (v) 20-21 min, 40% A; (vi) 21-22 min, 20% A; (vii) 22-
25 min, 98% A, and (viii) 25-30 min, 98% A. The HPLC-MS/MS was performed using a 
data-dependent acquisition (DDA) on positive ion mode at 1 s scan. Argon was used as 
collision gas with the collision energy ramp from 15 eV for low molecular weight (MW) 
peptides to 60 eV for high MW peptides. The tandem mass spectrometry (MS/MS) spectral 
data were deconvoluted using the MaxEnt 3 algorithm and their amino acid sequences were 
determined using the peptide sequencing software available in the Waters Biolynx
TM
 
software package.  
Microwave-assisted solid phase peptide synthesis 
Peptides were synthesised by microwave-assisted solid phase peptide synthesis (MW-SPPS) 
performed on a Liberty CEM microwave peptide synthesizer (Mathews, North Carolina, 
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USA) following a previously described method (Lafarga et al. 2014). Fractions containing 
the desired MW were identified using MALDI-TOF-MS and were pooled and lyophilized on 
a Genevac HT 4X lyophilizer (Genevac Ltd., Ipswich, UK). 
Statistical analysis 
All tests were replicated three times and mean values and S.D. were calculated. ANOVA 
one-way analysis was carried out using Minitab® v17 (Minitab Ltd., England, UK). Where 
significant differences were present, a Tukey pairwise comparison of the means was 
conducted to identify where the sample differences occurred.  
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RESULTS AND DISCUSSION 
Hemoglobin is the main protein in blood and represents approximately 10.3% of the total 
content of whole bovine blood (Bah et al. 2013). The yield of hemoglobin was calculated per 
litre of blood and was found to be 16.5 ± 0.2 g/L. The total protein content of the hemoglobin 
fraction, generated following the procedure described in Figure 1, was 95.5 ± 0.2%. In 
addition, the total moisture and ash content of the isolated protein were measured as 0.95 ± 
0.05 and 0.23 ± 0.02%, respectively. The isolated hemoglobin was analysed by MS by direct 
injection of the sample into a Q-TOF Premier mass spectrometer (Waters Corp., Milford, 
MA, USA) equipped with an electrospray ionization (ESI) source. The ESI-MS analysis of 
the isolated protein revealed a series of multiple charged species of bovine α- and β-globin 
chains ([M+11H]
11+ 
to [M+22H]
22+
). The deconvoluted mass spectrum of the sample, shown 
in Figure 2, showed the true MW of bovine α- and β-chains, which were 15054.5 and 
15956.0 Da, respectively. The differences between the expected and the deconvoluted masses 
for both α- and β-chains of bovine hemoglobin were less than 0.01%. Both, the raw and 
deconvoluted mass spectral data suggested that the isolated hemoglobin was a pure protein.  
In silico analysis 
Before in vitro hydrolysis, an in silico study was carried out in order to select a suitable 
enzyme to generate a hydrolysate rich in bioactive peptides with potential to inhibit ACE-I, 
renin, and DPP-IV. The use of in silico methods was shown previously as effective for 
predicting the release of bioactive peptides from known protein sequences and in the 
selection of enzymes and proteins for generation of bioactive peptides (Lacroix and Li-Chan 
2012, Lafarga et al. 2014, Lafarga et al. 2015). The hemoglobin protein fraction isolated in 
this study was found to be a good reservoir for generation of renin, ACE-I, and DPP-IV 
inhibitory peptides and hydrolysates for potential use in the food industry. Papain was the 
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most effective enzymes for the generation of known ACE-I and DPP-IV inhibitors from 
bovine hemoglobin in silico when compared to the enzymes pepsin, thermolysin, trypsin, and 
bromelain. No renin inhibitory peptides were generated from bovine hemoglobin by in silico 
cleavage using selected enzymes. This may be due to the limited reports of renin inhibitory 
peptides found in the literature to date. Indeed, only five renin-inhibitory peptides derived 
from food sources are currently available in BIOPEP compared to over 500 ACE-I-inhibitory 
peptides (Data accessed on April 2015) (Minkiewicz et al. 2008). Results are comparable to 
previous studies where no renin inhibitory peptides were predicted to be generated in silico 
from blood proteins (Lafarga et al. 2016). Bioactive peptides identified using in silico 
analysis included the di-peptide VE, generated using papain and corresponding to sequence 
f(71-72) of the α-chain of bovine hemoglobin. The peptide VE, was previously identified by 
Van Platerink et al. (2008) by LC-MS in a commercial milk hydrolysate and was reported to 
inhibit ACE-I. Moreover, papain was used previously for the generation of numerous ACE-I 
and renin inhibitors as well as antioxidant peptides from animal sources including bovine 
brisket sarcoplasmic proteins (Di Bernardini et al. 2012), plant proteins (He et al. 2013), 
blood (Lafarga et al. 2015), and seaweed (Fitzgerald et al. 2012). 
ACE-I- and renin-inhibitory activities in vitro 
The in vitro ACE-I and renin inhibitory activity of the generated hydrolysates was measured 
and is shown in Figure 3. At a concentration of 1 mg/mL, HB-1UFH inhibited ACE-I by over 
40% compared to the control which was assayed at a concentration of 1 mg/ml. The ACE-I 
inhibitory activity of the papain hydrolysate of bovine hemoglobin generated in this study 
was low compared to a previously generated hydrolysate obtained during hydrolysis of 
porcine hemoglobin with pepsin which inhibited ACE-I by over 60% (Deng et al. 2014). 
Purification by ultrafiltration using 10, 3 and 1 kDa membranes led to increased ACE-I-
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inhibitory activity compared to the HB-NUFH (p<0.05). Inhibition was also significantly 
higher in the HB-1UFH fraction compared to the HB-3UFH and HB-10UFH fractions 
(p<0.05). These results were consistent with previous studies where similar increases in 
bioactivities resulted from enrichment (Hyun and Shin 2000). It is well documented that 
peptidic ACE-I inhibitors usually consist of short amino acid sequences (Wu et al. 2006). The 
presence of high MW peptides in the HB-NUFH fraction may have contributed to the 
decrease in ACE-I-inhibitory activity not only by decreasing the concentration of small MW 
peptides in the sample but also by blocking the activity of smaller peptides.  
Furthermore, the renin-inhibitory activity of the generated papain hydrolysates of hemoglobin 
was measured at a concentration of 1 mg/mL compared to a positive control. It is well known 
that the inhibition of ACE-I is easier to achieve when compared to that of renin (Udenigwe et 
al. 2009). However, in this study, the renin-inhibitory activity was similar compared to that of 
ACE-I. At a concentration of 1 mg/mL, the fraction HB-1UFH was the most active with a 
percentage of renin inhibition of 40.25 ± 8.37%. Although it was previously suggested that 
the nature and position of the amino acid residues rather than the size of the peptide play a 
major role in the enhancement of renin inhibition (Mundi and Aluko 2014), purification by 
ultrafiltration led to a significant increase in the renin inhibitory activity of the HB-1UFH 
fraction compared to the HB-NUFH, HB-3UFH, and HB-10UFH fractions (p<0.05). These 
results are consistent with the fact that di-peptides were previously suggested as the most 
effective peptidic renin inhibitors (Li and Aluko 2010). The papain hydrolysate generated 
herein was more active inhibiting renin than previous blood protein hydrolysates reported in 
the literature. For example, Lafarga et al. (2015) generated a papain hydrolysate of a bovine 
fibrinogen-rich protein fraction which inhibited renin by 18.8% when tested at a 
concentration of 1 mg/mL. This is, to the best of our knowledge, the first study that used 
hemoglobin as a resource for generation of renin inhibiting hydrolysates and peptides. 
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However, the renin inhibitory values achieved in this study are similar to those obtained from 
a variety of natural sources in previous studies including an Alcalase® hydrolysates of 
kidney bean protein, which was found to inhibit renin by 20-40% at a concentration of 1 
mg/mL (Mundi and Aluko 2014), and hydrolysates of flaxseed protein with renin IC50 values 
ranging between 1.22-2.81 mg/mL (Udenigwe et al. 2009). 
DPP-IV-inhibitory activities in vitro 
The in vitro DPP-IV-inhibitory activity of the studied fractions was calculated and results are 
shown in Figure 3. The most active fractions, HB-1UFH and HB-10UFH inhibited DPP-IV 
by 45.26 ± 0.35 and 49.93 ± 1.28%, respectively when tested at a concentration of 1 mg/mL. 
DPP-IV IC50 values of HB-NUFH, HB-1UFH, HB-3UFH, and HB-10UFH were 1.10 ± 0.09, 
1.04 ± 0.22, 1.09 ± 0.09, and 0.99 ± 0.12 mg/mL, respectively. As well as for ACE-I and 
renin inhibitory properties, a slight increase in the DPP-IV inhibitory activity of HB-1UFH 
compared to the HB-NUFH was observed (p<0.005). Results obtained in this study are 
consistent with the fact that most of the peptides with DPP-IV-inhibitory activity described in 
the literature to date contain between two and eight amino acid residues in length (Lacroix 
and Li-Chan 2012). Indeed, the peptides IPI (diprotin A) and VPL (diprotin B), isolated for 
the first time from culture filtrates of Bacillus cereus BMF673-RF1, are known peptidic 
inhibitors of DPP-IV (Umezawa et al. 1984), and are used as positive controls in numerous 
screening studies. Even smaller MW components such as the amino acid residues tryptophan, 
methionine, and leucine were shown to present DPP-IV inhibitory activities (Nongonierma et 
al. 2013). The papain hydrolysates generated in this study presented DPP-IV IC50 values 
between 0.99 and 1.10 mg/mL. These values compared favourably with those obtained by 
trypsin hydrolysates of Amaranthus hypochondriacus L. proteins with IC50 values ranging 
from 1.2 to 2.0 mg/mL, depending on the enzyme to substrate ratio (Velarde-Salcedo et al. 
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2013), and a Flavourzyme® hydrolysate of Atlantic salmon gelatine with a DPP-IV IC50 
value of 1.35 mg/mL (Li-Chan et al. 2012). The IC50 values obtained herein, were also lower 
than those obtained from a trypsin hydrolysate of whey protein with an IC50 value of 1.51 
mg/mL, where the penta-peptide IPAVF, corresponding to β-lactoglobulin f(78-82) and with 
an IC50 value of 44.7 µM was responsible for the observed activity (Silveira et al. 2013). 
Peptide identification by de novo peptide sequencing 
The LC-MS/MS chromatogram of the papain hydrolysed peptides in the HB-1UFH fraction 
is shown in Figure 4. Figure 4 also shows the MS spectrum for the elucidated peptide HLP, 
where Y and B ions and possible internal ions were labelled. The HPLC profile from this 
enriched protein hydrolysate showed great peptide generation throughout the separation as 
papain cleaves at several amino acid sites. The identification of peptides was carried out 
using the Biolynx
TM
 peptide sequencing software for each MS/MS spectral data generated via 
DDA. Thirty short peptides of between two and six amino acids in length were identified by 
de novo peptide sequencing. Table 1 lists the identified amino acid sequences, their 
corresponding position in the parent protein, their observed masses, and their calculated 
masses. According to the manufacturer, the preferential cleavage sites of papain are the C-
terminal sides of arginine and lysine. Consequently, the majority of the peptides identified 
herein showed a prevalence of arginine and lysine residues in the C-terminal position. 
Identified peptides were compared to previously reported ACE-I, renin, and DPP-IV 
inhibitors available in the database BIOPEP (Minkiewicz et al. 2008). There were sequence 
similarities between the peptides identified in this study and previously reported ACE-I and 
DPP-IV inhibitors available in BIOPEP. Other amino acids sequences that are similar in 
peptides derived from other sources are also listed in Table 1. For example, the peptide LKG, 
corresponding to f(90-92) of the β-chain of bovine hemoglobin, was found to share the same 
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termination with the previously reported chemically synthesized ACE-I inhibitor KG 
(Cheung et al. 1980) and the DPP-IV inhibitor VFRELKDLKG, derived from milk (Lacroix 
and Li-Chan 2014).  
A number of the identified peptides were selected for chemical synthesis and bioassay 
assessment. Selected peptides were the di-peptides HR, YR, HF, and the tri-peptide HLP. 
These peptides were chosen for chemical synthesis as it is well known that di- and tri-
peptides are more likely to be resistant to degradation by digestive enzymes and are expected 
to be absorbed directly from the gastrointestinal tract into the blood circulatory system 
(Vermeirssen et al. 2004). Indeed, Iwai et al. (2005) identified several food-derived collagen 
short peptides rich in proline and hydroxyproline in human blood after oral ingestion of 
gelatine hydrolysates. Moreover, peptides chosen for chemical synthesis were selected based 
on the current knowledge of bioactive peptides and the known attributes of ACE-I and renin 
inhibitors (Lacroix and Li-Chan 2012, Li and Aluko 2010, Mundi and Aluko 2014, Wu et al. 
2006). The amino acid residue composition of a peptide and the position of the amino acid in 
the sequence are determinant in the ACE-I, renin, and DPP-IV inhibitory bioactivity of a 
peptide (Korhonen and Pihlanto 2006). The scores assigned by PeptideRanker to the 
identified peptides, shown in Table 1, were also taken into consideration when selecting the 
peptides for synthesis. PeptideRanker, available at http://bioware.ucd.ie, is a useful in silico 
tool that may be used to identify among a set of peptides those that may be more likely to be 
bioactive (Mooney et al. 2012). The peptide HF, for example, had a PeptideRanker score of 
0.95 and presented the hydrophobic residue phenylalanine in its C-terminus position, as 
previously suggested by Wu et al. (2006). Moreover, the peptide HLP had a proline in its C-
terminus residue which was suggested to aid resistance to degradation (Vermeirssen et al. 
2004) and to encourage ACE-I inhibition in tri-peptides (Wu et al. 2006). 
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Chemical synthesis and confirmation of bioactivity 
The di-peptides HR, YR, HF, and the tri-peptide HLP were chemically synthesised by MW-
SPPS and tested for ACE-I and renin inhibition in vitro. ACE-I and renin IC50 values were 
determined for active peptides by plotting the percentage of inhibition as a function of the 
concentration of test compound as shown in Figure 5. At a concentration of 1 mg/mL, the 
peptide HF did not inhibit renin. In turn, the peptides HR, YR and HLP showed renin IC50 
values of 7.09, 8.78, and 6.43 mM, respectively. These results were comparable to previously 
reported renin inhibitory peptides from natural sources such as the peptide IR, generated by 
enzymatic hydrolysis of pea protein with Alcalase® (Li and Aluko 2010), and the peptide 
IRLIIVLMPILMA, generated by enzymatic hydrolysis of seaweed protein with papain 
(Fitzgerald et al. 2012). The peptides IR and IRLIIVLMPILMA had renin IC50 values of 9.2 
and 3.3 mM, respectively. The peptides HR, YR, and HLP described in this study are the first 
renin-inhibitory peptides generated and characterized from bovine hemoglobin to date. These 
peptides were found not only to inhibit renin but also inhibit the enzyme ACE-I. 
Hydrolysates and peptides presenting both, renin and ACE-I inhibitory properties were 
recently suggested to provide better antihypertensive properties compared to hydrolysates or 
peptides that inhibit ACE-I alone (Udenigwe et al. 2009). 
ACE-I IC50 values found following bioassay were calculated as 191.66, 124.12, and 715.48 
µM for the peptides HR, YR and HLP, respectively. The peptide HF which did not inhibit 
renin, showed an ACE-I IC50 value of 221.28 µM. The ACE-I-inhibiting activity of the 
identified peptides was comparable to previously reported ACE-I-inhibiting peptides 
generated from bovine hemoglobin including 
TKAVEHLDDLPGALSELSDLHAHKLRVDPVNFKLLSHSLL, 
LDDLPGALSELSDLHAHKLRVDPVNFKLLSHSL, and LLSHSL which inhibited the 
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activity of ACE-I by half at a concentration of 366, 518, and 1095 µM, respectively (Adje et 
al. 2011). It was lower, however, than the activity of the peptides VVYPWT and 
LGFPTTKTYFPHF, which were generated from porcine hemoglobin and showed IC50 values 
of 6.02 and 4.92 µM (Yu et al. 2006). 
Prediction of resistance to gastrointestinal degradation and bitterness 
Many biologically active peptides never become clinically useful because of a number of 
factors including poor stability, low bioavailability and permeability through biological 
barriers, and low water solubility (Wang et al. 1999). The resistance of peptides to 
gastrointestinal enzyme degradation determines to a large extent their bioavailability 
(Vermeirssen et al. 2004). Computer simulations of proteolysis were carried out on bioactive 
peptides identified in this study in order to predict their stability to gastrointestinal digestion. 
Results suggest that the peptides HR, YR, HF, and HLP would be further broken down by the 
action of the enzymes pepsin, trypsin, and chymotrypsin, found in the gastrointestinal tract. 
Using in silico analysis, the peptides YR and HF were predicted to be cleaved by both, pepsin 
and chymotrypsin, into the amino acids tyrosine, arginine, histidine, and phenylalanine, 
respectively. The peptide HR was predicted to be cleaved by the action of chymotrypsin into 
the amino acid residues histidine and arginine. In addition, the tri-peptide HLP was cleaved 
by both, chymotrypsin and pepsin, to generate the di-peptides LP and HL. The peptide LP is 
a known bioactive peptide previously generated from rice bran protein and reported to inhibit 
DPP-IV in vitro (Hatanaka et al. 2012). Although in silico analysis is a useful tool to predict 
resistance of a protein or a peptide to enzymatic cleavage, in vivo studies in animal models 
are required in order to assess the bioavailability of a biologically active hydrolysate or 
peptide. 
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Moreover, although humans accept bitterness in certain products including coffee, we have a 
natural preference for sweet and fat tastes (Temussi 2012). Bioactive hydrolysates and 
peptides usually have a bitter taste and Western consumers do not seem to be willing to 
compromise taste for health benefits (Grasso et al. 2014). A number of methods have been 
used to predict the bitterness of a peptide. For example, the ‘Q rule’ formulated by Ney 
(1971), quantifies the bitterness of a peptide based on its amino acid composition, whereby a 
Q-value is calculated from the solubility data for each individual amino acids. According to 
this method, when the Q-value of a peptide, with a MW under 6 kDa, exceeds 1400 cal/mol, 
this peptide will be almost certainly bitter (Ney 1971). The Q-values for the peptides HR, 
YR, HF, and HLP were 625.0, 1525.0, 1500.0, and 1633.3 cal/mol, respectively. Obtained Q-
values suggest that the peptides YR, HF, and HLP may present bitter taste. However, 
although Ney’s rule can be applied to the majority of known peptides, there are exceptions. 
For example, Cho et al. (2004) characterized for flavor, chemical properties, and 
hydrophobicity a number of peptides derived from two commercial enzymatic hydrolysates 
of soy protein. In this study, the hydrophobicity data based on Q-values did not support Ney’s 
rule as a predictor of bitterness. Although it’s an expensive and time-consuming activity, the 
ideal route for quantifying bitterness is to use sensory evaluation panels (Spellman et al. 
2005). Despite the fact that bioactive hydrolysates and peptides usually have a bitter taste, 
industrial production of food-derived bioactive peptides does exist and include the tri-
peptides IPP and VPP which are found in the food product Calpis® sour milk (Calpis Food 
Industry Co., Ltd., Tokyo, Japan).   
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CONCLUSION 
This study demonstrates, for the first time, the potential of bovine hemoglobin as source of 
hydrolysates with renin as well as DPP-IV inhibitory properties. In addition, the renin 
inhibitory peptides identified herein are the first renin inhibitors identified from bovine 
hemoglobin. One novel ACE-I inhibitor, the bioactive peptide HF, as well as three novel 
multifunctional peptides which inhibited ACE-I and renin were identified. These 
multifunctional peptides were identified as HR, YR, and HLP and presented IC50 values 
comparable to previously reported biologically active peptides from animal and plant sources. 
The in vitro ACE-I and renin inhibitory activity of a peptide is not enough to evaluate their 
activity in the human body after ingestion, and in vivo studies should be carried out in order 
to assess the bioavailability of the generated hydrolysates and peptides after ingestion. 
Potential toxicity, allergenicity should as well be considered before inclusion of the generated 
hydrolysates and peptides into a food product and before human consumption.   
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TABLE 1. 1 
PEPTIDES IDENTIFIED FROM THE GENERATED PAPAIN HYDROLYSATE OF BOVINE HEMOGLOBIN BY HPLC-MS/MS. 2 
  3 
Amino acid 
sequence 
Parent protein 
Obtained 
mass charge 
(Da) 
Calculated 
mass (Da) 
PeptideRanker 
score* 
Similar ACE-I-inhibiting peptides** 
Similar DPP-IV-inhibiting 
peptides** 
AADK f(6-8) HBA 403.28 403.20 0.11 N/A AA, AAATP, AAAAG 
NFK 
f(98-100) HBA; 
f(101-103) HBB 
407.28 407.21 0.58 PGTAVFK 
IPAVFK 
HGAK f(59-62) HBA 411.28 411.22 0.20 FQKVVAK, IAK N/A 
KLR f(91-93) HBA 415.28 415.29 0.29 LDAQSAPLR N/A 
ALTK f(66-69) HBA 431.28 431.27 0.10 RMLGNTPTK,  RMLGQTPTK 
AL, ALGGA, ALAV, 
MWPTSSSTK 
HAAE f(21-24) HBA 426.28 426.18 0.08 IAE N/A 
ERM f(31-33) HBA 434.28 434.19 0.34 WRM WRM 
PVLQ f(123-126) HBB 455.28 455.27 0.18 GKKVLQ, LQ N/A 
NNPK f(55-58) HBB 471.28 471.24 0.22 
MKPWIQPK, EMPFPK, VPK, 
AMKPWIQPK, EMPFPK, MNPPK, 
PPK, VPAAPPK N/A 
GHAAE f(20-24) HBA 483.28 483.20 0.12 IAE N/A 
HF f(46-47) HBA 302.17 302.13 0.95 GHF N/A 
HR f(142-143) HBB 311.17 311.17 0.33 N/A N/A 
LKG f(90-92) HBB 316.27 316.21 0.30 KG, MKG 
VFRELKDLKG, LKPTPEGD, 
LKPTPEGDLEIL, VFRELKDLKG 
AVH f(121-123) HBA 325.17 325.17 0.09 N/A N/A 
YR f(141-142) HBA 337.17 337.17 0.53 N/A N/A 
HGK f(62-64) HBB 340.17 340.18 0.23 
FGK, FFVAPFPFEVFGK, FPFEVFGK, 
GK, FPEVFGK, FFVAPFPEVFGK N/A 
AHK f(89-91)HBA 354.17 354.20 0.13 HLAHK, VGINYWLAHK, HK LAHKALCSEK 
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LSH 
f(49-51; 102-104) 
HBA 
355.17 355.18 0.18 YIPIQYVLSR 
N/A 
LGR f(27-29) HBB 344.27 344.21 0.62 GR N/A 
LAR f(113-115) HBB 358.27 358.23 0.33 ALKAWSVAR, YLYEIAR, AR LAPSLPGKPKPD 
LTK f(67-69) HBA 360.27 360.23 0.07 RMLGNTPTK,  RMLGQTPTK EQLTKCEVFR, MWPTSSSTK 
HLP f(113-115) HBA 365.17 365.20 0.58 
PAVVLP, NILP, PQNILP, ILP, VLP, 
PLP, LPLP, LLP, GLP 
HL 
VGGH f(18-21) HBA 368.14 368.18 0.31 GH VGL 
HLDDLK f(86-91) HBB 739.32 739.38 0.28 FALPQYLK HL, VGGSDLQALK 
EFT f(120-122) 395.28 395.16 0.24 
QAFT, SSIQSQPQAFT, 
VHSSIQSQPQAFT 
N/A 
SELSDLHAHK f(82-91) HBA 1048.48 1048.53 0.18 HLAHK, VGINYWLAHK, HK N/A 
LSDLHAHKLR f(84-93)HBA 1188.61 1188.67 0.40 LDAQSAPLR N/A 
ELSDLHAHKLR f(83-93) HBA 1317.67 1317.71 0.37 LDAQSAPLR N/A 
SELSDLHAHKLR f(82-93) HBA 1404.70 1404.74 0.41 LDAQSAPLR N/A 
HGSA f(51-54) HBA 370.18 370.16 0.22 CMENSA N/A 
* Data accessed from PeptideRanker, available at http://bioware.ucd.ie/ on April 2015 
** Data accessed from BIOPEP, available at http://www.uwm.edu.pl/biochemia/index.php/pl/biopep on April 2015 
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